TCP
BLUE

Tourbillon Capital Partners’s bluebird bio BLUE Stock Holding History

Tourbillon Capital Partners’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,860
Closed -$7.85M – 42
2018
Q2 		$7.85M Buy
+3,860
New +$8.8M 0.3% 63

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tourbillon Capital Partners's BLUE Position: Q3 2018 in Review

Tourbillon Capital Partners sold out of bluebird bio (BLUE) in Q3 2018, closing a stake of 6,948 shares — an estimated $14.1M sold.

Tourbillon Capital Partners first reported a position in BLUE in Q4 2014 and held it in 4 quarters. The position peaked at $42.1M in Q2 2015. 288 funds tracked by Wall St. Rank hold BLUE as of Q3 2018.

  • Tourbillon Capital Partners reported no remaining bluebird bio position as of Q3 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 6,948 bluebird bio shares in Q3 2018, an estimated $14.1M.
  • Tourbillon Capital Partners first reported a position in bluebird bio in Q4 2014 and held it in 4 quarters.
  • Tourbillon Capital Partners's bluebird bio position peaked at $42.1M in Q2 2015.
  • 288 funds tracked by Wall St. Rank held bluebird bio as of Q3 2018.

Based on Tourbillon Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.